



OPEN

Retraction Note: Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance *in vitro* and *in vivo* by selectively inhibiting the efflux activity of ABCB1

Published online: 30 December 2025

Yi-Jun Wang, Bhargav A. Patel, Nagaraju Anreddy, Yun-Kai Zhang, Guan-Nan Zhang, Saeed Alqahtani, Satyakam Singh, Suneet Shukla, Amal Kaddoumi, Suresh V. Ambudkar, Tanaji T. Talele & Zhe-Sheng Chen

Retraction of: *Scientific Reports* <https://doi.org/10.1038/srep42106>, published online 09 February 2017

The Editors have retracted this Article.

After publication, concerns were raised regarding highly similar images within the Article and with another publication from the same authors¹. Specifically:

- the H&E image in the Paclitaxel + TTT-28 in Figure 6B of this article appears to overlap the H&E image in the DOX in Figure 6B of¹;
- the H&E image in the Vehicle in Figure 6B of this article appears to overlap the H&E image in the Vehicle in Figure 6A of¹;
- the H&E image in the TTT-28 in Figure 6C of this article appears to overlap the H&E image in the Vehicle in Figure 6B of¹;
- the ABCB1 image in the Paclitaxel in Figure 6C of this article appears to overlap the ABCB1 image in the DOX-TNP in Figure 6B of¹;
- the Active Caspase-3 image in the Vehicle in Figure 6C of this article appears to overlap the Caspase-3 image in the Vehicle in Figure 6B of¹;
- the Active Caspase-3 image in the TTT-28 in Figure 6C of this article appears to overlap the Caspase-3 image in the TNP in Figure 6B of¹;
- the Active Caspase-3 image in the TTT-28 in Figure 6B of this article appears to overlap the Caspase-3 image in the Vehicle in Figure 6A of¹;
- the Cleaved PARP-1 image in the TTT-28 in Figure 6B of this article appears to overlap the PARP image in the TNP in Figure 6A of¹;
- the Cleaved PARP-1 image in the Vehicle in Figure 6B of this article appears to overlap the PARP image in the TNP in Figure 6A of¹;
- the Cleaved PARP-1 image in the Vehicle in Figure 6C of this article appears to overlap PARP image in TNP in Figure 6B in¹;
- the H&E image in the Vehicle in Figure 6B of this article appears to overlap the H&E image in the TTT-28 in Figure 6B of this article.

The Authors confirmed similarities but were unable to provide an adequate explanation to the concerns raised. The Editors therefore no longer have confidence in the presented data.

Additionally, according to the data presented in Figures 3A and 4A, the tumour burden in mice exceeded the limits stated in the NIH Guidelines for Humane Endpoints in Animal Study Proposals.

Yi-Jun Wang, Bhargav A. Patel, Yun-Kai Zhang, Guan-Nan Zhang, Suresh V. Ambudkar, Tanaji T. Talele and Zhe-Sheng Chen disagree with the retraction. Nagaraju Anreddy, Satyakam Singh, Suneet Shukla, and Amal Kaddoumi did not respond to the correspondence from the Editors about this retraction. The Editors have not been able to obtain a current email address for author Saeed Alqahtani.

Reference

1. Wang, Y. J. et al. Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin. *Oncotarget* 7(5), 5877 (2015).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Publisher 2025